Clinical trial
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell…
NCT04543591 · Alexion Pharmaceuticals, Inc., Industry · Active, not recruiting
Key facts
| NCT number | NCT04543591 |
|---|---|
| Title | Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant |
| Official title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants Who Have Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplant (HSCT) |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thrombotic Microangiopathy |
| Intervention type | Biological, Other |
| Interventions | Ravulizumab, Placebo, Best supportive care |
| Enrollment | 148 |
| Start date | Dec 10, 2020 |
| Primary completion | Sep 19, 2025 |
| Completion | Mar 20, 2026 |
| First posted | Sep 10, 2020 |
| Last update posted | Feb 6, 2026 |
| Countries | Australia, Belgium, Brazil, Canada, China, France, Germany, Greece, Israel, Italy, Japan, Netherlands and 5 more |
At a glance
- 100–999 Study sites
- No Results posted
- 10–99 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: